Dandan Chen1, Junyin Feng2, Lei Huang3, Qinglin Zhang2, Jiequn Wu2, Xiangcheng Zhu4, Yanwen Duan4, Zhinan Xu3. 1. Department of Chemical and Biological Engineering, Zhejiang University, Hangzhou, China; Huzhou Center of Bio-synthetic Innovation, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Huzhou, China. 2. Huzhou Center of Bio-synthetic Innovation, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Huzhou, China. 3. Department of Chemical and Biological Engineering, Zhejiang University, Hangzhou, China. 4. Hunan Engineering Research Center of Combinatorial Biosynthesis and Natural Product Drug Discovery, Changsha, Hunan, China; Xiangya International Academy of Translational Medicine, Central South University, Changsha, Hunan, China.
Abstract
Erythromycins (Ers) are clinically potent macrolide antibiotics in treating pathogenic bacterial infections. Microorganisms capable of producing Ers, represented by Saccharopolyspora erythraea, are mainly soil-dwelling actinomycetes. So far, Actinopolyspora erythraea YIM90600, a halophilic actinomycete isolated from Baicheng salt field, is the only known Er-producing extremophile. In this study, we have reported the draft genome sequence of Ac. erythraea YIM90600, genome mining of which has revealed a new Er biosynthetic gene cluster encoding several novel Er metabolites. This Er gene cluster shares high identity and similarity with the one of Sa. erythraea NRRL2338, except for two absent genes, eryBI and eryG. By correlating genotype and chemotype, the biosynthetic pathways of 3'-demethyl-erythromycin C, erythronolide H (EH) and erythronolide I have been proposed. The formation of EH is supposed to be sequentially biosynthesized via C-6/C-18 epoxidation and C-14 hydroxylation from 6-deoxyerythronolide B. Although an in vitro enzymatic activity assay has provided limited evidence for the involvement of the cytochrome P450 oxidase EryFAc (derived from Ac. erythraea YIM90600) in the catalysis of a two-step oxidation, resulting in an epoxy moiety, the attempt to construct an EH-producing Sa. erythraea mutant via gene complementation was not successful. Characterization of EryKAc (derived from Ac. erythraea YIM90600) in vitro has confirmed its unique role as a C-12 hydroxylase, rather than a C-14 hydroxylase of the erythronolide. Genomic characterization of the halophile Ac. erythraea YIM90600 will assist us to explore the great potential of extremophiles, and promote the understanding of EH formation, which will shed new insights into the biosynthesis of Er metabolites.
Erythromycins (Ers) are clinically potent macrolide antibiotics in treating pathogenic bacterial infections. Microorganisms capable of producing Ers, represented by Saccharopolyspora erythraea, are mainly soil-dwelling actinomycetes. So far, Actinopolyspora erythraea YIM90600, a halophilic actinomycete isolated from Baicheng salt field, is the only known Er-producing extremophile. In this study, we have reported the draft genome sequence of Ac. erythraea YIM90600, genome mining of which has revealed a new Er biosynthetic gene cluster encoding several novel Er metabolites. This Er gene cluster shares high identity and similarity with the one of Sa. erythraeaNRRL2338, except for two absent genes, eryBI and eryG. By correlating genotype and chemotype, the biosynthetic pathways of 3'-demethyl-erythromycin C, erythronolide H (EH) and erythronolide I have been proposed. The formation of EH is supposed to be sequentially biosynthesized via C-6/C-18 epoxidation and C-14 hydroxylation from 6-deoxyerythronolide B. Although an in vitro enzymatic activity assay has provided limited evidence for the involvement of the cytochrome P450 oxidase EryFAc (derived from Ac. erythraea YIM90600) in the catalysis of a two-step oxidation, resulting in an epoxy moiety, the attempt to construct an EH-producing Sa. erythraea mutant via gene complementation was not successful. Characterization of EryKAc (derived from Ac. erythraea YIM90600) in vitro has confirmed its unique role as a C-12 hydroxylase, rather than a C-14 hydroxylase of the erythronolide. Genomic characterization of the halophile Ac. erythraea YIM90600 will assist us to explore the great potential of extremophiles, and promote the understanding of EH formation, which will shed new insights into the biosynthesis of Er metabolites.
Erythromycins (Ers) are a series of 14-membered macrolide antibiotics showing broad-spectrum activity against various gram-positive bacteria [1]. Since its first discovery in Saccharopolyspora erythraea (Sa. erythraea, formerly known as Streptomyces erythraeus), Ers have been reported clinically potent in treating certain types of pathogenic bacterial infections [2], [3]. However, natural Ers are facilely decomposable under acidic conditions, which will result in the loss of clinic activity and the appearance of undesirable side effects [4]. To minimize acidic instability, second-generation Ers such as clarithromycin [5], azithromycin [6], and roxithromycin [7] with modified macrolide skeletons were generated. Nowadays, the rising bacterial resistance encountered by second-generation Ers becomes noticeable. The possible resistance mechanism may come from ribosomal modification (erm) or macrolide efflux (mef) [8], [9]. In either way, the drug activity will be reduced dramatically. Therefore, the development of third-generation Ers, represented by cethromycin (ABT-773) [10], EP-420 [11], and BAL-19403 [12], was addressed to overcome the bacterial resistance problem.As a model organism for laboratory researches and a parental strain for industrial production, Sa. erythraea has been extensively and systemically investigated. The erythromycin biosynthetic gene cluster in Sa. erythraeaNRRL2338 has been characterized and validated by the genome sequence-based analysis [13], [14]; while erythromycin A (Er-A), B (Er-B), and C (Er-C) have also been classified as its major products via numerous fermentative analyses [15]–[17]. Correlation between genotype and chemotype has facilitated us to understand the biosynthesis of Ers in Sa. erythraea: the assembling of the 6-deoxyerythronolide B (6-dEB) skeleton from one propionyl-coenzyme A (CoA) and six methylmalonyl-CoAs by a set of multifunctional type I polyketide synthases (PKSs) named 6-deoxyerythronolide B synthases (DEBSs) [18], [19], and the sequential post-PKS modifications, including two hydroxylations, two glycosylations, and one methylation, to form the final product, Er-A [20] (Fig. 1).
Figure 1
Biosynthetic pathway of the final Er product, Er-A.
Three DEBSs, EryAI-AIII, are responsible for the generation of the 16-membered lactone, 6-dEB; Tailoring enzymes catalyze sequential reactions, including two hydroxylations, two glycosylations, and one methylation, to obtain the final product, Er-A.
Biosynthetic pathway of the final Er product, Er-A.
Three DEBSs, EryAI-AIII, are responsible for the generation of the 16-membered lactone, 6-dEB; Tailoring enzymes catalyze sequential reactions, including two hydroxylations, two glycosylations, and one methylation, to obtain the final product, Er-A.So far, the reported microorganisms capable of producing Ers are mainly soil actinomycetes. In addition to Sa. erythraea, Ers have also been detected in certain strains of Arthrobacter and Nocardia species [21], [22]. Comparing with those soil-dwelling microbes, the original Er-producing strain Actinopolyspora erythraea (Ac. erythraea) YIM90600 in this study was isolated from Baicheng salt field in Xingjiang province, northwestern of China [23]. As the representatives of halophilic species, Actinopolyspora species normally require high salinity environment for growth. The metabolites analyses of Ac. erythraea YIM90600 from large-scale fermentation cultures have confirmed the presence of several normal Er biosynthetic intermediates and novel congeners, along with three linear polyketide actinopolysporin A, B, C and a known antineoplastic antibiotic tubercidin [24]. Specifically, the identified Er metabolites in YIM90600 include Er-C, 3′-N-demethyl-Er-C, erythronolide B (EB), erythronolide H (EH) and erythronolide I (EI) [25] (Fig. 2), which hints the possible existence of an Er-like gene cluster in the genome of YIM90600. Meanwhile, the presence of novel erythronolides, EH and EI, may indicate some distinct biosynthetic pathways in YIM90600. Moreover, EH exhibites identical chemical structure to EB except the C-6/C-18 epoxidation and the C-14 hydroxylation, thus it could be served as an ideal aglycone for further chemical or enzymatic modification [25].
Figure 2
The identified Er metabolites in Ac. erythraea YIM90600.
EB and Er-C are normal Er intermediates, while 3′-N-demethyl-Er-C, EH, and EI are novel Er congeners that have rarely been reported.
The identified Er metabolites in Ac. erythraea YIM90600.
EB and Er-C are normal Er intermediates, while 3′-N-demethyl-Er-C, EH, and EI are novel Er congeners that have rarely been reported.In this work, we have taken advantage of whole-genome sequencing and computer-assisted analysis to identify and characterize the Er biosynthetic gene cluster in Ac. erythraea YIM90600. The established genotype-chemotype correlation could facilitate us to decipher the possible formation of Er congeners in YIM90600 and may shed new insights into the Er biosynthetic pathway, as well as the development of novel Er derivatives.
Materials and Methods
Bacterial strains, plasmids, and reagents
The strains and plasmids used in this study were summarized in Table 1. Primer sequences were listed in Table S1 in File S1. Chemicals and biochemical materials were purchased from standard commercial sources.
Table 1
Bacterial strains and plasmids used and constructed in this study.
Strains/plasmids
Characteristic(s)
Source/reference
E. coli
DH5α
Host for general cloning
Invitrogen
ET12567(pUZ8002)
Donor strain for conjugation between E. coli and Streptomyces
[26]
BL21(DE3)
Host for protein expression
Novagen
EX104
Derivative of BL21(DE3) containing an EryFSa-expression vector
This study
EX105
Derivative of BL21(DE3) containing an EryFAc-expression vector
This study
EX106
Derivative of BL21(DE3) containing an EryKSa-expression vector
This study
EX107
Derivative of BL21(DE3) containing an EryKAc-expression vector
This study
Ac. erythraea
YIM90600
Original Er-producing strain, a halophilic actinomycete from slat field
[23]
Sa. erythraea
ZL2001
Recombinant Er-producing strain, enhancing the expression of eryK and eryG, introducing artificial attB sites for site-specific recombination
[15], [16]
EX101
Derivative of ZL2001, eryFSa in-frame deletion mutant
This study
EX102
Derivative of ZL2001, eryBVSa in-frame deletion mutant
This study
EX103
Derivative of EX101 containing pEX103 integrated by the ΦC31 integrase-mediated recombination with the genotype of PermE*-eryFAc
This study
Plasmids
pMD18-T simple
E. coli subcloning vector
TaKaRa
pET28a
E. coli protein expression vector
Novagen
pOJ260
E. coli-Streptomyces shuttle vector containing the aac(3)IV gene
[43]
pSET152
E. coli-Streptomyces shuttle vector containing aac(3)IV gene, the ΦC31 attP site and integrase gene
[43]
pWHM79
pGEM3zf derivative carrying a 0.5-kb fragment containing the ermE* promotor
[42]
pEX1011
pMD19-T derivative carrying the upstream fragment of eryFSa
This study
pEX1012
pMD19-T derivative carrying the downstream fragment of eryFSa
This study
pEX1021
pMD19-T derivative carrying the upstream fragment of eryBVSa
This study
pEX1022
pMD19-T derivative carrying the downstream fragment of eryBVSa
This study
pEX101
pOJ260 derivative for in-frame deletion within eryFSa
This study
pEX102
pOJ260 derivative for in-frame deletion within eryBVSa
This study
pEX1031
pMD19-T derivative carrying the eryFAc gene fragment with its terminator
This study
pEX103
pSET152 derivative for the PermE*-controlled expression of eryFAc
This study
pEX1041
pMD19-T derivative carrying the eryFSa gene
This study
pEX104
pET28a derivative for heterologous expression of EryFSa
This study
pEX1051
pMD19-T derivative carrying the eryFAc gene
This study
pEX105
pET28a derivative for heterologous expression of EryFAc
This study
pEX1061
pMD19-T derivative carrying the eryKSa gene
This study
pEX106
pET28a derivative for heterologous expression of EryKSa
This study
pEX1071
pMD19-T derivative carrying the eryKAc gene
This study
pEX107
pET28a derivative for heterologous expression of EryKAc
This study
DNA isolation, manipulation, and sequencing
DNA isolation and manipulation in Escherichia coli (E. coli) and Sa. erythraea were performed according to standard salting-out protocol [26]. The procedure for extraction and purification of Ac. erythraea genomic DNA was modified by replacing the lysozyme digestion with liquid-nitrogen grinding. Primer synthesis and DNA sequencing were performed by Shanghai GeneCore Biotechnology Inc. Whole-genome sequencing of Ac. erythraea YIM90600 was performed by Beijing Genomics Institute (BGI)-Shenzhen. Draft genome sequence of Ac. erythraea YIM90600 was deposited at DDBJ/EMBL/GenBank with the accession number JPMV00000000. DNA sequences covering left, middle, and right fringes of the Er gene cluster were deposited in GenBank with accession numbers KJ143518, KJ143519, and KJ143520, respectively.
Gene disruption of eryF and eryBV in Sa. erythraea ZL2001
The genomic DNA of Sa. erythraeaZL2001 was served as the template for PCR amplification.To inactivate EryFSa in the original strain ZL2001, a 2.02 kb fragment amplified by primers pFLf and pFLr and a 2.13 kb fragment amplified by primers pFRf and pFRr were initially cloned into the pMD19-T vector, giving pEX1011 and pEX1012, respectively. After DNA sequencing to confirm the fidelity, the 2.02 kb EcoRI/XbaI and 2.13 kb XbaI/HindIII fragments were recovered and then co-ligated into the EcoRI/HindIII site of pOJ260, yielding the recombinant plasmid pEX101, in which a 771 bp in-frame coding region (corresponding to AA71-AA327 of the deduced product EryFSa) of eryF was deleted.To inactivate EryBVSa in the original strain ZL2001, a 2.04 kb fragment amplified by primers pBVLf and pBVLr and a 2.08 kb fragment amplified by primers pBVRf and pBVRr were initially cloned into the pMD19-T vector, giving pEX1021 and pEX1022, respectively. After DNA sequencing to confirm the fidelity, a recombinant plasmid pEX102 was constructed following the same strategy, in which a 786 bp in-frame coding region (corresponding to AA76-AA337 of the deduced product EryBVSa) of eryBV was deleted.The constructs pEX101 and pEX102 were introduced individually into Sa. erythraeaZL2001 by intergeneric conjugation from E. coli ET12567/pUZ8002. Following the procedure described previously [15], the exconjugants were subjected to a double-crossover recombination event, leading to the generation of mutant strains EX101 and EX102, respectively. The genotype of each mutant was validated by PCR amplification (Figure S1 and Figure S2 in File S1).
Gene complementation of eryF in Sa. erythraea EX101
The genomic DNA of Ac. erythraea YIM90600 was served as the template for PCR amplification.To complement eryF into the eryF-deleting mutant EX101, a 1.29 kb fragment obtained by using the primers pAcF-Cf and pAcF-Cr was initially cloned into the pMD19-T vector, giving pEX1031. After sequencing to confirm the fidelity, the 1.29 kb HindIII/XbaI fragment and a 0.49 kb EcoRI/HindIII fragment containing PermE* were recovered and co-ligated into the EcoRI/XbaI site of pSET152 to yield pEX103.The construct pEX103 was introduced into Sa. erythraea EX101 by intergeneric conjugation from E. coli ET12567/pUZ8002, following the procedure described previously [16]. The colonies presenting apramycin-resistant phenotype were identified as exconjugants, leading to the generation of the recombinant strains EX103. The genotype of the complementary strain was confirmed by PCR amplification-coupled sequencing described previously [16], [27] (Figure S3 in File S1).
Fermentation and chemical analyses of the Er metabolites
Cultivation of the Sa. erythraea strains and compound extraction from the fermentative broths were carried out according to the procedures described previously [16]. High performance liquid chromatography-electrospray ionization-mass spectrometry (HPLC-ESI-MS) analysis was performed on a Shimadzu 2010 liquid chromatograph-mass spectrometer (Shimadzu, Japan), and a Diamonsil C18 5 µ reverse-phase column (250×4.6 mm; catalog no. 99603; Dikma, USA). The analytical method was developed with a flow rate of 1 ml/min and column temperature at 23 °C. The column was eluted using an 35 min gradient program: 0–3 min, constant 85% A/15% B; 3–6 min, a linear gradient to 60% A/40% B; 6–12 min, constant 60% A/40% B; 12–19 min, a linear gradient to 45% A/55% B; 19–22 min, a linear gradient to 15% A/85% B; and 22–35 min, constant 15% A/85% B (solvent A, 5 mM NH4COOH, 0.5‰ HCOOH in H2O; solvent B, 0.5‰ HCOOH in CH3CN). High-resolution ESI-MS (HR-ESI-MS) analysis was carried out on a maXis 4G ultra-high resolution time-of-flight (UHR-TOF) mass spectrometer (Bruker Daltonics, USA). ESI-MS-MS analysis was carried out on an LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scientific, USA).
Expression and purification of EryFSa, EryFAc, EryKSa and EryKAc
A 1.22 kb eryF gene fragment and a 1.20 kb eryK gene fragment were amplified from the genomic DNA of Sa. erythraeaZL2001 using primer pairs pSaFf/pSaFr and pSaKf/pSaKr, respectively. The PCR products were individually cloned into the pMD19-T vector. After sequencing to confirm the fidelity, the inserts were recovered and ligated into the NdeI/EcoRI site of pET28a, yielding pEX104 and pEX106 for expression of N-terminal 6 x His-tagged EryFSa and EryKSa, respectively. Similarly, a 1.22 kb eryK gene fragment and a 1.20 kb eryK gene fragment were amplified from the genomic DNA of Ac. erythraea YIM90600 using primer pairs pAcFf/pAcFr and pAcKf/pAcKr, respectively. Following the same sub-cloning steps, pEX105 and pEX107 were constructed for producing N-terminal 6 x His-tagged EryFAc and EryKAc, respectively.The constructs pEX104, pEX105, pEX106 and pEX107 were introduced individually into E. coliBL21 (DE3) by transformation, yielding four recombinant strains EX104, EX105, EX106 and EX107, respectively. Each strain was cultured in Luria Bertani (LB) medium supplemented with 50 µg/ml kanamycin at 37 °C and 250 rpm until OD600 reached 0.6–0.8. To induce protein expression, 0.1 mM isopropyl-β-D-thiogalactopyranoside (IPTG), 0.1 mM Fe(NH4)2(SO4)2, and 0.5 mM 5-aminolevulinic acid (ALA) were added to the culture before further incubation at 18 °C and 250 rpm for 28–32 hrs. Purification and quantification of the targeted proteins were carried out according to the methods described previously [28] (Figure S4 in File S1).
Characterization of EryFSa, EryAc, EryKSa and EryKAc
To characterize EryFSa, EryAc, EryKSa and EryKAc as cytochrome P450 proteins, the CO binding difference spectra within the range of 350–500 nm, were recorded as previously described [28] (Figure S5 in File S1). Following the procedure described before, substrate binding spectra were recorded after the addition of 6-dEB dissolved in dimethyl sulfoxide (DMSO) [28] (Figure S9 in File S1). Measurement of ultraviolet-visible (UV-vis) absorbance was performed on a JASCO V-530 UV/vis spectrophotometer (Jasco, Japan).A 50 µl reaction mixture in 10% (v/v) DMSO containing 50 µM 6-dEB, 1 mM NADPH, 0.1 U/ml ferredoxin-NADP+ reductase, 50 µg/ml ferredoxin, 10 mM glucose-6-P, 1 U/ml glucose-6-P dehydrogenase and 2 µM EryFSa (or EryFAc) in 50 mM Tris-HCl buffer (pH 7.5) was incubated at 30°C for 2 hrs. For a negative control, EryFSa (or EryFAc) was inactivated by heating at 100°C for 15 min. Similarly, 0.2 mM Er-B, was incubated with 2 µM EryKSa (or EryKAc) (other components were the same as the reaction mixture mentioned above). For a negative control, EryKSa (or EryKAc) was inactivated by heating at 100°C for 15 min. Reactions were initiated by addition of target enzyme, and terminated by adding an equal volume of acetonitrile to precipitate the enzyme. After removal of the precipitate by centrifugation, the supernatant was subjected to HPLC-ESI-MS, HR-ESI-MS and ESI-MS-MS analyses.
Results and Discussion
Genomic characterization of the halophilic actinomycete Ac. erythraea YIM90600
Halophiles are conveniently grouped according to their physiological requirement for salinity environment. Slight halophiles, mainly isolated from marine, favor a living condition of 2–5 % NaCl. Moderate halophiles prefer a wider NaCl concentration range of 5–20 %. Extreme halophiles, represented by the acknowledged halobacteria and halococci, grow well at NaCl concentrations higher than 20 % [29]. In this study, the original strain Ac. erythraea YIM90600, first isolated from Baicheng salt field of China, is a typical moderate halophile [23]. By using ISP4 (International Streptomyces Project 4) agar media supplemented with different concentrations of NaCl, we have validated that YIM90600 favors an environment of 10–20 % NaCl. Meanwhile, YIM90600 is able to grow at NaCl concentrations higher than 25 %, but not in low salinity environment. According to previous literatures on taxonomy, the genus Actinopolyspora, belonging to the suborder Acintopolysporineae, includes high G+C Gram-positive bacteria [30].The genomic DNA of Ac. erythraea YIM90600 was extracted following a modified salting-out method from a 4-day TSB (Tryptic Soy Broth) culture supplemented with 15 % NaCl. The resultant DNA sample, showing a mean length of about 25 kb and OD260/OD280 of 1.78, was qualified for further genomic sequencing. Whole-genome sequencing of YIM90600 was performed with a strategy of Illumina paired-end sequencing technology [31]. About 960 Mb raw data of a 500bpPCR-free index library and about 518 Mb raw data of a 2000bpPCR-free index library were generated. Clean data filtered from both libraries were assembled into 37 scaffolds and 86 contigs. De novo assembly yielded a 5.36 Mb draft genome sequence with a mean G+C content of 68.76 %. Sequence similarity searching for known proteins was conducted in the COG (Clusters of Orthologous Groups) database, the Swiss-Prot protein database, and the KEGG (Kyoto Encyclopedia of Genes and Genomes Pathway) database. A total of 5303 genes covering 84.39 % of the genome were annotated for their function. The average gene length was determined as 852 bp. Searching against the KEGG database indicated that 2293 genes were mapped to 170 KEGG pathways [32]. Additionally, 102 genes involved in metabolism of terpenoids and polyketides were identified, which suggested that they were most likely responsible for the biosynthesis of Er metabolites. Genomic characterization of the halophilic actinomycete Ac. erythraea YIM90600 would help us to explore its potential for the production of secondary metabolites, and the biosynthetic mechanisms of YIM90600-derived natural products.
Identification and preliminary analysis of the Er gene cluster in Ac. erythraea YIM90600
Genome mining of Ac. erythraea YIM90600 enabled us to explore its genetic basis for Er production. By searching the 5.36 Mb draft genome sequence for debs homologues, we have identified three separated fragments which could be merged to form a full-length Er gene cluster in YIM90600. The newly identified ORFs (Open Reading Frames) were named following their homologous genes in Sa. erythraea (Fig. 3). To avoid confusion, two superscripts, Sa and Ac, were used to distinguish genes from Sa. erythraea and Ac. erythraea, respectively.
Figure 3
Comparative analysis of the two gene clusters of Sa. erythraea NRRL2338 and Ac. erythraea YIM90600.
The genes share high identity (82–93 %) and similarity (88–96 %). Most of the genes exhibit the same order and direction as their homologues, except for eryBI and eryG, which are absent in the newly identified gene cluster.
Comparative analysis of the two gene clusters of Sa. erythraea NRRL2338 and Ac. erythraea YIM90600.
The genes share high identity (82–93 %) and similarity (88–96 %). Most of the genes exhibit the same order and direction as their homologues, except for eryBI and eryG, which are absent in the newly identified gene cluster.The Er-encoding genes in YIM90600 shares high identity (82–93 %) and similarity (88–96 %) with their homologues in Sa. erythraeaNRRL2338 [13], [14], suggesting that their transcriptional products present similar functions. A series (EryAI-AIII) are PKS enzymes responsible for the assembling of the macrolactone, 6-dEB [18], [19]; B series (EryBII-BVII) and C series (EryCI-CVI) are enzymes related to the formation and attachment of the sugar residues, L-mycarose and D-desosamine, respectively [33], [34]; Tailoring enzymes, including cytochrome P450 oxidases (EryF and EryK) and glycosyltransferases (EryBV and EryCIII), catalyze the post-PKS modifications of polyketide skeleton [20] (Fig. 1). With comparison, the Er-encoding genes in both strains exhibited the same order and direction, except that eryBI and eryG are absent in YIM90600 (Fig. 3). Interestingly, there have been different opinions on the biochemical function of EryBI. The amino acid sequence suggests that EryBI belongs to β-glucosidase, indicating its involvement in bioconversion of sugar residues [35]. Based on its B series nomenclature, EryBI should be involved in L-mycarose bioconversion [14]. From the perspective of homology, EryBI also showed 61% identity and 74 % similarity to OleR in oleandomycin biosynthesis [36], suggesting it might play an important role as resistant protein. However, neither of these viewpoints is tenable since the inactivation of EryBI exerted no effect on the Er production in Sa. erythraea
[37]. Therefore, eryBI could be a nonfunctional gene, and this assumption has been further confirmed by our genomic analyses results that the discovered Er-producing machinery in YIM90600 does not contain any eryBI homologue. Comparative analysis of the two Er gene clusters would allow us to study the biosynthetic mechanisms of Er metabolites in YIM90600, further characterization of which would also provide insights into the generality in Er formation, as well as the specificity in EH and EI biosyntheses.
Genotype-chemotype correlation of Er metabolites in Ac. erythraea YIM90600
The distinct Er metabolites profile of Ac. erythraea YIM90600 has presented a certain consistency to its genotype [25]. The absence of normal main Er compounds such as Er-A and Er-B in YIM90600 is probably due to the absence of eryG, a gene encoding a methyltransferase responsible for the O-methylation at C’’-3 of the mycarosyl residue [38], thus the intermediate Er-C is accumulated. Based on the biosynthetic pathway, the P450 oxidase EryF is responsible for the C-6 hydroxylation of 6-dEB, and the resultant EB is the first intermediate after the tailoring steps [20], [39]. The disappearance of EB in Sa. erythraea may because of the fast and efficient subsequent modification step of C-3 O-glycosylation; while the accumulation of EB in YIM90600 suggests that its glycosylation step is relatively not sufficient, probabaly due to either inefficiency of the glycosyltransferase activity or inadequacy of the sugar supply. 3′-N-demethyl-Er-C differs from Er-C in the N-methylation degree at C′-3 of the desosaminyl residue. According to that, EryCVI responsible for the N-dimethylation step during desosamine biosynthesis [33], [34] may only exert its partial activity in YIM90600, which could lead to the generation of monomethylated product.The biosynthetic pathways of novel EH and EI have been proposed before [25] (Fig. 4). The DEBS thioesterase (TE) domain in YIM90600 was predicted dual functional in catalyzing two different intramolecular cyclizations, resulting in both 14- and 6-membered lactones. The sequential C-6/C-18 epoxidation and C-14 hydroxylation of the 14-membered lactone 6-dEB could generate EH; while the 6-membered lactone might undergo C-6 and C-12 hydroxylations, C-2/C-3 dehydration, and C-9 spiroketalization to form EI. Appearance of the shunt metabolite EH hinted us the existence of certain cytochrome P450 oxidase(s) in catalyzing the typical epoxy moiety and the additional hydroxyl group.
Figure 4
Proposed biosynthetic pathways of the Er metabolites in Ac. erythraea YIM90600 modeled on erythromycin biosynthesis in Sa. erythraea
[25].
The EryAIII TE domain is supposed dual functional. The TE-catalyzed intramolecular cyclization releases the 14-membered 6-dEB via path a, and a 6-membered lactone via path b. Both serve as substrates for further modifications.
Proposed biosynthetic pathways of the Er metabolites in Ac. erythraea YIM90600 modeled on erythromycin biosynthesis in Sa. erythraea
[25].
The EryAIII TE domain is supposed dual functional. The TE-catalyzed intramolecular cyclization releases the 14-membered 6-dEB via path a, and a 6-membered lactone via path b. Both serve as substrates for further modifications.
Characterization of the cytochrome P450 protein EryFAc via in vitro enzymatic activity assay and in vivo gene complementation
Base on our hypothesis, EryF, acting as a C-6 hydroxylase for 6-dEB in Sa. erythraea, may catalyze a successive two-step oxidation in Ac. erythraea, which coverts 6-dEB into 6, 18-epoxy-EB via the intermediate EB. To evaluate whether EryFAc is capable of catalyzing a four-electron oxidation, a corresponding in vitro enzymatic activity assay of the P450 oxidase has been conducted. The N-6 x His-tagged recombinant proteins, EryFSa and EryFAc, were respectively expressed, purified, and characterized as cytochrome P450 proteins (Figure S4 and Figure S5 in File S1) [28].Sa. erythraeaZL2001 is a recombinant strain with introduction of 8 copies of attB (attachment of bacterial) sites in its genome to enhance actinophage ΦC31 integrase-mediated site-specific recombination [15], [16], and possesses the overexpression of EryK and EryG to strengthen the production of the most potent component, Er-A (Figure S10 in File S1). In-frame deletion of eryF in ZL2001 generated a mutant Sa. erythraea EX101, which has completely abrogated the virulence of natural Er components, validating the indispensability of EryFSa. The fermentation of EX101 led to the accumulation of 6-dEB, the substrate for in vitro enzymatic activity assay, and the generation of novel 6-deoxy-Ers (Fig. 5A, and Figure S11 in File S1). The appearance of 6-deoxy-Ers suggested that inactivation of EryFSa could not completely block the subsequent Er tailoring steps in Sa. erythraea. The identity of 6-dEB was confirmed by HR-ESI-MS and ESI-MS-MS analyses (Figure S6A and Figure S7 in File S1). Meanwhile, the one-step oxidation product EB was produced in an eryBV-deleting mutant, Sa. erythraea EX102 (Fig. 5B). In consistence, in-frame deletion of eryBV led to the detection of Er metabolites with only desosaminyl residue (Figure S12 in File S1), further indicating the tolerance of tailoring enzymes. HR-ESI-MS and ESI-MS-MS analyses were carried out to accomplish the identity of EB (Figure S6B and Figure S8 in File S1).
Figure 5
HPLC-ESI-MS analyses of the fermentation cultures of Sa. erythraea EX101 and EX102.
(A) Total ion current chromatogram (i), and reconstructed base peak chromatogram for 6-dEB (ii) of the fermentation products of EX101. ESI-MS data recorded at the retention time of 27.06 min (iii). (B) Total ion current chromatogram (iv), and reconstructed base peak chromatogram for EB (v) of the fermentation products of EX102. ESI-MS data recorded at the retention time of 15.96 min (vi).
HPLC-ESI-MS analyses of the fermentation cultures of Sa. erythraea EX101 and EX102.
(A) Total ion current chromatogram (i), and reconstructed base peak chromatogram for 6-dEB (ii) of the fermentation products of EX101. ESI-MS data recorded at the retention time of 27.06 min (iii). (B) Total ion current chromatogram (iv), and reconstructed base peak chromatogram for EB (v) of the fermentation products of EX102. ESI-MS data recorded at the retention time of 15.96 min (vi).The in vitro assays using 6-dEB and EryFSa (or EryFAc) were carried out. In the presence of EryFAc, 6-dEB was consumed accordingly to generate EB, as well as a possible new product, showing its positive ion peak at m/z 423.3. In the presence of EryFSa, no apparent ion peak corresponding to such new product was detected (Fig. 6). Further HR-ESI-MS analysis has eventually established the molecular formula of this new product as C21H36O7 ([M+Na]+ m/z calculated 423.2353, found 423.2342), suggesting its identity to 6, 18-epoxy-EB, which differs from EB with an distinct epoxide group (Figure S6C in File S1).
Figure 6
HPLC-ESI-MS analyses of the in vitro enzymatic reactions catalyzed by EryFSa and EryFAc, respectively.
(A) Total ion current chromatograms indicating the in vitro conversion of 6-dEB to EB in the absence of active EryFAc (i), in the presence of active EryFAc (ii), or in the presence of active EryFSa (iii). (B) Total ion current chromatogram (iv) and reconstructed base peak chromatogram for 6, 18-epoxy-EB (v) of the EryFAc reaction mixture. (C) Total ion current chromatogram (vi) and reconstructed base peak chromatogram for 6, 18-epoxy-EB (vii) of the EryFSa reaction mixture.
HPLC-ESI-MS analyses of the in vitro enzymatic reactions catalyzed by EryFSa and EryFAc, respectively.
(A) Total ion current chromatograms indicating the in vitro conversion of 6-dEB to EB in the absence of active EryFAc (i), in the presence of active EryFAc (ii), or in the presence of active EryFSa (iii). (B) Total ion current chromatogram (iv) and reconstructed base peak chromatogram for 6, 18-epoxy-EB (v) of the EryFAc reaction mixture. (C) Total ion current chromatogram (vi) and reconstructed base peak chromatogram for 6, 18-epoxy-EB (vii) of the EryFSa reaction mixture.The original EH-producing strain Ac. erythraea YIM90600 is not suitable for large-scale fermentation, because of its long cell growth cycle and harsh fermentative condition, as well as its low titers of Er metabolites [23], [25]. On the contrary, the genetic recombinant strain Sa. erythraeaZL2001, showing favorable physiological properties and high Er productivity, can be served as an ideal host for EH production [15]. In addition, the artificial attB sites in ZL2001 are quite convenient for genetic manipulation [16].Inspired by the previous success in generating new Er analogues via heterologous expression of OleP, a cytochrome P450 oxidase catalyzing an epoxidation of the oleandomycin lactone ring [40], [41], we have attempted to investigate whether in vivo gene complementation of eryF into the eryF-deleting strain would lead to the accumulation of EH in such mutant. The pEX103, a pSET152-derived plasmid containing eryF gene fragment under the control of a potent promoter P
[42], was introduced into EX101 to yield the recombinant strain Sa. erythraea EX103 (Figure S3 in File S1). Its genotype was validated as attL-linear pEX103-attR
[16], [27]. EX103 has restored the production of major Er components including Er-A, Er-B, and Er-C (Fig. 7), confirming the successful introduction of the target gene fragment P- eryF at the artificial attB site, as well as the association of such new gene to continue the biosynthesis of Ers. However, neither EH nor 6, 18-epoxy-EB was detected in the fermentation cultures of EX103 (Figure S13 in File S1).
Figure 7
HPLC-ESI-MS analysis of the fermentation culture of Sa. erythraea EX103.
Total ion current chromatogram (i), and reconstructed base peak chromatograms for 6-deoxy-Er-A (ii), Er-A (iii), 6-deoxy-Er-B (iv), Er-B (v), 6-deoxy-Er-C (vi), Er-C (vii), 6-deoxy-Er-D (viii), and Er-D (ix) are recorded. Note that 6-deoxy-Er-A and Er-B, as well as 6-deoxy-Er-C and Er-D share the same molecular weights and similar polarities, their base peaks are thus overlapping.
HPLC-ESI-MS analysis of the fermentation culture of Sa. erythraea EX103.
Total ion current chromatogram (i), and reconstructed base peak chromatograms for 6-deoxy-Er-A (ii), Er-A (iii), 6-deoxy-Er-B (iv), Er-B (v), 6-deoxy-Er-C (vi), Er-C (vii), 6-deoxy-Er-D (viii), and Er-D (ix) are recorded. Note that 6-deoxy-Er-A and Er-B, as well as 6-deoxy-Er-C and Er-D share the same molecular weights and similar polarities, their base peaks are thus overlapping.According to our analysis, the unique two-step oxidation catalyzed by EryFAc in the halophile Ac. erythraea YIM90600 may count on the insufficient conversion of EB to 3-O-mycarosyl-EB. Thus, the redundant EB could induce the occurrence of second oxidation catalyzed by EryFAc and the formation of 6,18-epoxy-EB, which finally leads to the production of a small amount of EH. Therefore, the invalidation of EryFAc to catalyze a successive two-step oxidation in Sa. erythraea mutant may due to the limited acquisition of EB, which is quite efficiently converted to 3-O-mycarosyl-EB. Further genetic manipulation targeting on EryBV shall provide us more clues to decipher such divergence.
Characterization of the cytochrome P450 protein EryKAc via in vitro enzymatic activity assay
The additional hydroxyl group of EH at C-14 could be catalyzed by a regiospecific P450 oxidase. The C-12 hydroxylation of Er-D (or Er-B) in Sa. erythraea is catalyzed by EryK, hinting a possibility of its additional function as a C-14 hydroxylase in Ac. erythraea to form EH. Two recombinant P450 proteins, EryKSa and EryKAc, were expressed, purified and characterized respectively (Figure S4 and Figure S5 in File S1).Using standard Er-B as the substrate, the enzymatic activities of EryKSa and EryKAc were tested in vitro. In the presence of EryKSa (or EryKAc), Er-B was consumed accordingly with the generation of Er-A (Fig. 8), confirming that the proteins were in the active form and the function of EryKAc as a C-12 hydroxylase in generating Er-C and 3′-N-demethyl-Er-C in Ac. erythraea. And then, 6-dEB was incubated with both EryFSa and EryKSa (or with both EryFAc and EryKAc). However, no apparent ion peak corresponding to 12-hydroxyl-EB or EH was detected (Figure S14 in File S1).
Figure 8
HPLC-ESI-MS analyses of the in vitro enzymatic reactions catalyzed by EryKSa and EryKAc, respectively.
Total ion current chromatograms indicating standard Er-B (red circle, i) and Er-A (blue lozenge, ii), the in vitro conversion of Er-B to Er-A in the absence of active EryKSa (iii), in the presence of active EryKSa (iv), in the absence of active EryKAc (v), or in the presence of active EryKAc (vi).
HPLC-ESI-MS analyses of the in vitro enzymatic reactions catalyzed by EryKSa and EryKAc, respectively.
Total ion current chromatograms indicating standard Er-B (red circle, i) and Er-A (blue lozenge, ii), the in vitro conversion of Er-B to Er-A in the absence of active EryKSa (iii), in the presence of active EryKSa (iv), in the absence of active EryKAc (v), or in the presence of active EryKAc (vi).
Conclusions
Based on genome sequencing and bioinformatics analysis, we have identified a new Er biosynthetic gene cluster in a halophilic actinomycete Ac. erythraea YIM90600. This Er gene cluster shares high identity and similarity with the one of Sa. erythraea
[13], [14], but lacks two genes eryBI and eryG. Correlation of genotype and chemotype has increased our understanding in the biosynthetic mechanism of Er metabolites in YIM90600. EH, a novel erythronolide featuring an epoxy moiety, is supposed to be a shunt product from C-6/C-18 epoxidation and C-14 hydroxylation of 6-dEB. The in vitro enzymatic activity assay of EryFAc suggested the generation of a new metabolite with the molecular formula C21H36O7 (although the molecular ion current of which was significantly less than that of EB), supporting our assumption that EryFAc, acting as a regiospecific P450 oxidase, is capable of catalyzing a successive two-step oxidation to form the epoxide of EH. However, subsequent in vivo genetic manipulation suggested that EryFAc could only catalyze one-step oxidation in Sa. erythraea. The in vitro enzymatic activity assay of EryKAc supported its role as a C-12 hydroxylase in generating Er-C and 3′-N-demethyl-Er-C, rather than a C-14 hydroxylase in EH formation. Although the biosynthesis of EH is still under discussion, exploration of the genetic background of YIM90600 and preliminary biosynthetic studies on its novel Er metabolites shall reveal the potential of extremophiles and shed new insights into Er biosynthetic pathways.This file contains Figure S1-Figure S14 and Table S1. Figure S1. Construction and genotype verification of the eryF-deleting mutant, Sa. erythraea EX101. (A) Sa. erythraea EX101 with a 771 bp deletion within eryF is constructed via a double-crossover event. (B) Gel electrophoresis analysis of the PCR products amplified from the genomic DNAs of Sa. erythraeaZL2001 (lane 1), EX101 (lane 2), and the single-crossover exconjugant (lane 3), using primer pair pFf/pFr. Figure S2. Construction and genotype verification of the eryBV-deleting mutant, Sa. erythraea EX102. (A) Sa. erythraea EX102 with a 786 bp deletion within eryBV is constructed via a double-crossover event. (B) Gel electrophoresis analysis of the PCR products amplified from the genomic DNAs of Sa. erythraeaZL2001 (lane 1), EX102 (lane 2), and the single-crossover exconjugant (lane 3), using primer pair pBVf/pBVr. Figure S3. Construction of the gene complementation mutant, Sa. erythraea EX103. The gene fragment P is introduced into the artificial attB sites of Sa. erythraea EX101 via the actinophage ΦC31 integrase-mediated site-specific recombination. Figure S4. SDS-PAGE analysis of the purified recombinant proteins with 6 x His-tag at the N terminus. Recombinant EryFSa (lane 1) exhibited a molecular mass of 47.4 kDa, recombinant EryFAc (lane 2) exhibited a molecular mass of 47.6 kDa, recombinant EryKSa (lane 3) exhibited a molecular mass of 46.0 kDa, and recombinant EryKAc (lane 4) exhibited a molecular mass of 46.3 kDa. Figure S5. CO difference spectra of the cytochrome P450 oxidases, EryFSa, EryFAc, EryKSa and EryKAc. UV-vis absorbance of both EryFSa (A) and EryFAc (B) exhibits a Soret peak at 423 nm under reducing condition, which shifts to 448 nm after binding of CO. UV-vis absorbance of both EryKSa (C) and EryKAc (D) exhibits a Soret peak at 420 nm under reducing condition, which shifts to 448 nm after binding of CO. Figure S6. HR-ESI-MS analyses of 6-dEB, EB, and the proposed 6, 18-epoxy-EB. A, purified 6-dEB with a molecular formula as C21H38O6, showing [M+Na]+ at m/z 409.2579, B, purified EB with a molecular formula as C21H38O7, showing [M+Na]+ at m/z 425.2517, C, an EryFAc-catalyzed enzymatic reaction containing a compound with a molecular formula as C21H36O7, showing [M+Na]+ at m/z 423.2342. Figure S7. Proposed fragmentation scheme for 6-dEB and the ESI-MS-MS product ion spectrum of 6-dEB. Figure S8. Proposed fragmentation scheme for EB and the ESI-MS-MS product ion spectrum of EB. Figure S9. Substrate binding spectra for 6-dEB bound to the cytochrome P450 oxidases, EryFSa and EryFAc. UV-vis absorbance of both EryFSa (A) and EryFAc (B) exhibits a Soret peak at 423 nm (green), which shifts to 392 nm after the addition of 6-dEB (blue). The Soret peaks at 392 nm increase with higher concentration of 6-dEB dissolved in the protein solutions (red). Figure S10. HPLC-ESI-MS analysis of the fermentation culture of Sa. erythraeaZL2001. Total ion current chromatogram (i), and reconstructed base peak chromatograms for Er-A (ii), Er-B (iii), Er-C (iv), and Er-D (v) are recorded. Figure S11. HPLC-ESI-MS analysis of the fermentation culture of Sa. erythraea EX101. Total ion current chromatogram (i), and reconstructed base peak chromatograms for 6-deoxy-Er-A (ii), 6-deoxy-Er-B (iii), 6-deoxy-Er-C (iv), and 6-deoxy-Er-D (v) are recorded. Figure S12. HPLC-ESI-MS analysis of the fermentation culture of Sa. erythraea EX102. Total ion current chromatogram (i), and reconstructed base peak chromatograms for 5-O-desosaminyl-EB (ii), 12-hydroxyl-5-O-desosaminyl-EB (iii) are recorded. Figure S13. HPLC-ESI-MS analysis of the fermentation culture of Sa. erythraea EX103. Total ion current chromatogram (i), and reconstructed base peak chromatograms for EH (ii), 6, 18-epoxy-EB (iii) are recorded. Figure S14. HPLC-ESI-MS analyses of the in vitro enzymatic reactions catalyzed by EryFAc and EryKAc, and by EryFSa and EryKSa, respectively. (A) Total ion current chromatogram (i) and reconstructed base peak chromatogram for EB (ii), 6, 18-epoxy-EB (iii), 12-hydroxyl-EB (iv), EH (v) of the EryFAc and EryKAc reaction mixture. (B) Total ion current chromatogram (i) and reconstructed base peak chromatogram for EB (ii), 6, 18-epoxy-EB (iii), 12-hydroxyl-EB (iv), EH (v) of the EryFSa and EryKSa reaction mixture. Table S1. Primers used for genetic manipulation and protein expression in this study.(DOC)Click here for additional data file.
Authors: G M Bright; A A Nagel; J Bordner; K A Desai; J N Dibrino; J Nowakowska; L Vincent; R M Watrous; F C Sciavolino; A R English Journal: J Antibiot (Tokyo) Date: 1988-08 Impact factor: 2.649
Authors: Guoqiang Wang; Deqiang Niu; Yao-Ling Qiu; Ly Tam Phan; Zhigang Chen; Alexander Polemeropoulos; Yat Sun Or Journal: Org Lett Date: 2004-11-25 Impact factor: 6.005
Authors: Calum J Walsh; Caitriona M Guinane; Colin Hill; R Paul Ross; Paul W O'Toole; Paul D Cotter Journal: BMC Microbiol Date: 2015-09-16 Impact factor: 3.605